Search

everythinglearnresearchcommunity

for

Search:↓

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.

COVID-19 may trigger or worsen rapid hair loss in alopecia areata.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.

A woman's hair loss, resembling an autoimmune condition, improved after treatment, but requires ongoing checks due to potential serious associations.

Adalimumab may cause severe hair loss in some patients.

Dupilumab for skin problems might reactivate hair loss in some patients.

Effective treatments for severe alopecia areata are still lacking.

Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.

Oral minoxidil helps hair regrowth in 80% of alopecia patients, but only 18% see cosmetic improvement.

A COVID-19 vaccine may trigger severe hair loss in rare cases.

Stopping azathioprine improved hair loss and bone marrow issues.

High dose methylprednisolone effectively stops hair loss and promotes regrowth in acute diffuse alopecia areata.

Minoxidil caused unwanted hair growth in a child, but stopped after stopping treatment.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

The model helps understand alopecia areata and suggests treatment strategies.

The model helps understand alopecia areata and suggests better treatment strategies.

The model helps understand alopecia areata and suggests ways to improve treatment by targeting immune issues.

These hair loss conditions might be part of a spectrum, not separate issues.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.

The 2003 guidelines suggest that while some treatments can regrow hair in alopecia areata, none alter the disease's progression, and wigs may be the best option for extensive hair loss.

COVID-19 infection may trigger alopecia areata in some patients.

The document concludes that recognizing specific histological features of different nonscarring alopecias is crucial for accurate diagnosis and understanding hair loss progression.